Modelling in tumour biology part II: Modelling cancer therapy

European Journal of Surgical Oncology

Volumn 26, Issue 2, 2000, Pages 181-188

  Rew, D A ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; MODEL; PRIORITY JOURNAL;

EID: 0034061987     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.1999.0767     Document Type: Article

References (60)

1. Priestman TJ. The rationale of cytotoxic drug therapy in Cancer chemotherapy; an introduction. Chapter 4. Springer Verlag Berlin. 1989;53-69.
2. Alberts B. The cell as a collection of protein machines. Cell. 92:1998;291-294.
3. Lehnert M, Twentyman P (Eds). Multidrug Resistance in Cancer: A special issue. Eur J Cancer. 32A:1996;911-1086.
4. Liu LF. DNA topoisomerase poisons as antitumour drugs. Ann Rev Biochem. 58:1989;351-375.
5. Smith PJ. Topoisomerase inhibitors: new twists to anticancer drug action. Oncology Today. 3:1991;4-9.
6. Hedley DW. Flow cytometric assays of anticancer drug resistance. Annals NY Acad Sci. 677:1993;341-353.
7. Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol. 16:1989;156-165.
8. Weinstein RS, Kuszak JR, Kluskens LP, Coon JS. P-glycoproteins in pathology; the MDR gene family in humans. Hum Pathol. 21:1990;34-48.
9. Kerr DJ, Kaye SB. MDR in haematological malignancies. Haematology Reviews. 4:1990;61-64.
10. Gottesman MM, Pastan I. Multidrug resistance- a review. Ann Rev Biochem. 62:1993;385-427.
11. Krishan A, Sauerteig A. Flow cytometric monitoring of cellular resistance to cancer chemotherapy. In: Flow cytometry: Principles and clinical application. KD Bauer, RE Duque and TV Shankey (Eds). Williams and Wilkins New York. 1992;459-467.
12. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer. 60:1989;815-818.
13. Twentyman PR. Approaches to the circumvention of cytotoxic drug resistance. Haematology Reviews. 4:1990;65-74.
14. Ramu A, Glaubiger D, Fuks Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparinol analogs. Cancer Res. 44:1984;4392-4395.
15. Foglesong PD, Reckord C, Swink S. Doxorubicin inhibits topoisomerase I. Cancer Chemother Pharmacol. 30:1992;123-125.
16. Foxwell BM, Mackie A, Ling V, Ryttel B. MDR related p-glycoprotein as a cyclosporin binding protein. Mol Pharmacol. 36:1989;543-546.
17. Gosland MP, Lum BE, Sikic BL. Reversal by cetoperazone of resistance to etoposide, doxorubicin and vinblastine in MDR human sarcoma cells. Cancer Res. 49:1989;6901-6905.
18. DeVita VT. The relationship between tumour mass and resistance to chemotherapy. Cancer. 51:1983;1209-1220.
19. Tannock IF. Conventional cancer therapy: promise broken or promise delayed. Lancet. 351 (Suppl. II):1998;9-16.
20. Schipper H, Turley EA, Baum M. Viewpoint: A new biological framework for cancer research. Lancet. 348:1996;1149-1151.
21. Steel GG. Growth kinetics of tumours. London: Oxford University Press. 1977.
22. Tannock I. Cell kinetics and chemotherapy, a critical review. Cancer Treat Rep. 62:1978;1117-1133.
23. Van Putten LM. Cell Kinetics, a guide for chemotherapy? Controversies in Cancer, Chapter 13. Masson Publishing. 1979;117-119.
24. Norton L. Thoughts on a role for cell kinetics in cancer chemotherapy; Controversies in Cancer. New York: Masson Publishing USA Inc. 1979;105-115.
25. Simpson-Herren L. Kinetic perturbations during cancer therapy. Annals NY Acad Sci. 397:1982;88-100.
26. Potten CS, Kellett M, Roberts S, Rew DA, Wilson GD. Measurement of in vivo proliferation in human colorectal mucosa using bromodeoxyuridine. Gut. 33:1992;71-78.
27. Tannock I. Experimental chemotherapy and concepts related to the cell cycle. Int J Radiat Biol. 49:1986;335-355.
28. Tannock, I, Experimental chemotherapy. In Tannock I and Hill RP.The basic science of oncology, 2nd Edn. New York: McGraw Hill, 1992, 338, 59.
29. Hill BT, Price LA. An experimental biological basis for increasing the therapeutic index of clinical cancer therapy. Annals NY Acad Sci. 397:1982;72-87.
30. Mauro F, Gohde W, Schumann J, Teodori L, Spano M. Considerations in the design of possible cell cycle effective drugs. Int J Radiat Biol. 49:1986;307-333.
31. Kerr JFR, Wyllie AH, Currie AH. Apoptosis, a basic biological phenomenon with wider implications in tissue kinetics. Br J Cancer. 26:1972;239-245.
32. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell. 65:1991;1097-1098.
33. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to programmed cell death. Br J Cancer. 64:1991;192-196.
34. Dive C, Evans CA, Whetton AD. Induction of apoptosis-new targets for cancer chemotherapy. Semin Cancer Biol. 3:1992;417-427.
35. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:1994;539-542.
36. Begg AC. Derivation of cell kinetic parameters from human tumours after labelling with Boromodeoxyuridine or iodo- deoxyuridine. Br Inst Radiol Report. 19:1989;113-119.
37. Wilson GD. Assessment of human tumor proliferation using bromodeoxyuridine - current status. Acta Oncologica. 30:1991;903-910.
38. Gorczyca W, Sarode V, Juan G, Melamed M, Darzynkiewicz Z. Laser scanning cytometric analysis of Cyclin B1 in primary human malignancies. Human Pathol. 10:1997;457-462.
39. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anti-cancer agents XII. On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother Rep. 35:1964;1-111.
40. Kearsley JH. Cytotoxic chemotherapy for common adult malignancies: the emperor's new clothes revisited? Br Med J. 293:1986;871-876.
41. Clarke M, Collins R, Davies C, Goodwin J, Gray R, Peto R. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1465.
42. Hill RP. Cellular basis of Radiotherapy. In Tannock I (Ed). The Basic Science of Oncology. Chapter 15, Elsevier Press. 1986;237-255.
43. Hill, RP, Experimental Radiotherapy. In Tannock I (Ed) The Basic Science of Oncology, Chapter 16, Oxford: Elsevier Press, 1986, 256, 77.
44. Kummermehr J, Trott K-R. Rate of repopulation in a slow and fast growing mouse tumour. In Karcher KH et al. (eds). Progress in Radio-oncology II, New York: Raven Press. 1982;299-308.
45. Tubiana M. The kinetics of tumour cell proliferation and radiotherapy. Br J Radiol. 44:1971;325-347.
46. Denekamp J. Cell kinetics and radiation biology. Int J Radiat Biol. 49:1986;357-380.
47. Peters LJ, Brock WA, Chapman JD, Wilson GD. Predictive assays of tumour radiocurability. Am J Clin Oncol (CCT). 11:1988;275-287.
48. Dische S, Saunders MI. Continuous, hyperfractionated, accelerated radiotherapy (CHART). Br J Cancer. 59:1989;325-326.
49. Poste G. Cellular heterogeneity in malignant neoplasms and the therapy of metastases. Annals NY Acad Sci. 397:1982;34-48.
50. Rew DA. Heterogeneity, biodiversity and bioperversity in human solid tumours. Eur J Surg Oncol. 22:1996;469-473.
51. Jain RK. Barriers to drug delivery in solid tumours. Scientific American. 271:1994;58-65.
52. Fidler IJ, Ellis LM. The implications of angiogensis for the biology and therapy of cancer metastasis. Cell. 79:1994;185-188.
53. Jiang WG, Puntis MCA, Hallett MB. Molecular and cellular basis for cancer invasion and metastasis: implications for treatment. Br J Surgery. 81:1994;1576-1580.
54. Naguib R, Adams A, Horne C, Angus B, Smath A, Sherbet G, Lennard T. Prediction of nodal metastasis and prognosis in breast cancer: a neural model. Anticancer Res. 17:1997;2735-2741.
55. Hanahan D. A flanking attack on cancer. Nature Medicine. 4:1998;13-14.
56. Sikora K. Genes, dreams and cancer. Br Med J. 308:1994;1217-1221.
57. Ledermann JA. Radiolabelled antibodies for cancer therapy. Hospital Update. 1:1989;56-65.
58. Russell SJ, Llewelyn MB, Hawkins RE. Principles of antibody therapy. Br Med J. 305:1992;1424-1428.
59. Hawkins RE, Llewelyn MB, Russell SJ. Adapting antibodies for clinical use. Br Med J. 305:1992;1348-1352.
60. Krishan A, Shridar KS, Davila E, Vogel C, Sternheim W. Patterns of anthracycline retention in human tumour cells. Cytometry. 8:1987;306-314.